參考文獻(xiàn)/References:
[1] Zhang H, Yang T, Wu M, et al. Intrahepatic cholangiocarcinoma: Epidemiology, risk factors, diagnosis and surgical management [J]. Cancer Lett, 2016, 379(2): 198-205.[2] 張文杰, 孫倍成. 膽管癌的治療進(jìn)展 [J]. 肝膽胰外科雜志, 2020, 32(6): 326-330.[3] Valle J, Wasan H, Palmer D H, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer [J]. N Engl J Med, 2010, 362(14): 1273-1281.[4] Lamarca A, Palmer D H, Wasan H S, et al. ABC-06 | A randomised phase Ⅲ, multi-centre, open-label study of active symptom control(ASC)alone or ASC with oxaliplatin / 5-FU chemotherapy(ASC+mFOLFOX)for patients(pts)with locally advanced / metastatic biliary tract cancers(ABC)previously-treated with cisplatin/gemcitabine(CisGem)chemother-apy[J]. J Clin Oncol, 2019, 37(15S): 4003.[5] Lin R, Fan N, Wu G, et al. A phase 2 study of fluorouracil/leucovorin in combination with paclitaxel and oxaliplatin as a salvage treatment in patients with refractory or relapsed advanced gastric cancer [J]. J Chemother, 2015, 27(1): 52-56.[6] Lin R B, Fan N F, Guo Z Q, et al. A phase Ⅱ study of 5-fluorouracil/leucovorin in combination with paclitaxel and oxaliplatin as first-line treatment for patients with advanced gastric cancer [J]. J Chemother, 2008, 20(6): 744-748.[7] Shroff R T, Javle M M, Xiao L, et al. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial [J]. JAMA Oncol, 2019, 5(6): 824-830.[8] Ulusakarya A, Karaboue A, Ciacio O, et al. A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancer [J]. BMC Cancer, 2020, 20(1): 515.[9] Belkouz A, de Vos-Geelen J, Mathot R A A, et al. Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: an open-label, single arm, phase 2 trial [J]. Br J Cancer, 2020, 122(5):634-639.[10] Phelip J M, Edeline J, Blanc J F, et al. Modified FOLFIRINOX versus CisGem first-line chemotherapy for locally advanced non resectable or metastatic biliary tract cancer(AMEBICA)-PRODIGE 38: Study protocol for a randomized controlled multicenter phase Ⅱ/Ⅲ study [J]. Dig Liver Dis, 2019, 51(2): 318-320.[11] Perkhofer L, Berger A W, Beutel A K, et al. Nal-IRI with 5-fluorouracil(5-FU)and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial(AIO-YMO HEP-0315)an open label, non-comparative, randomized, multicenter phase Ⅱ study [J]. BMC Cancer, 2019, 19(1): 990.[12] Roth M T, Goff L W. Gemcitabine, cisplatin, and nab-paclitaxel for patients with advanced biliary tract cancer: closing the GAP [J]. JAMA Oncol, 2019, 5(6): 831-832.